Luteolin
A rodent neuroinflammation literature wearing a human supplement label.
D+
Evidence grade
D
Worth it
$15-25/month
Typical cost
DoseProducts typically provide 50 to 100 mg/day; the combination studies used similar amounts within multi-ingredient formulas. Dietary luteolin (celery, parsley, peppers, chamomile) runs in single milligrams. No dose has been established by a trial of luteolin itself.
BasisLuteolin is a flavonoid with a large animal literature and a human literature consisting of uncontrolled combination-product reports.
Luteolin is a flavonoid found in celery, parsley, peppers, and chamomile, sold for brain fog, neuroinflammation, allergies (via mast-cell stabilization claims), and post-viral syndromes. We grade Luteolin D+ on evidence and D for worth-it at about $15-25 per month.
What it does
Luteolin is a flavonoid found in celery, parsley, peppers, and chamomile, sold for brain fog, neuroinflammation, allergies (via mast-cell stabilization claims), and post-viral syndromes. It is one of the flavonoid batch that entered this queue from list frequency rather than from trial data.
What the research says
Human data exist only inside combination products and one small open literature
Evidence: weak. Luteolin's human footprint: a proprietary luteolin formulation was studied in children with autism spectrum disorders in small open and retrospective reports (improvements in behavior ratings, no placebo control), and luteolin combined with PEA appears in small European studies for pain and neuroinflammation. No randomized trial isolates luteolin for any outcome in any population.
The neuroinflammation reputation is preclinical
Evidence: weak. In cell and animal models luteolin suppresses microglial activation and mast-cell mediators, the basis of its 'brain inflammation' marketing. Rodent neuroinflammation models have an extensive record of not predicting human supplement effects, and this library grades the human file, which for luteolin is effectively empty.
Luteolin is a flavonoid with a large animal literature and a human literature consisting of uncontrolled combination-product reports. Its marketing borrows credibility from the broader flavonoid class and from conditions (brain fog, neuroinflammation, post-viral syndromes) where desperate demand meets untestable claims. Graded on the human file, there is almost nothing here yet, and D+ records exactly that: not disproven, simply untested where it counts.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at D. About $20 a month at common doses. Derived from the October 2026 worth-it model.
Typical cost
$15-25/month
Common form, not a brand recommendation
Dosage context established
Products typically provide 50 to 100 mg/day; the combination studies used similar amounts within multi-ingredient formulas. Dietary luteolin (celery, parsley, peppers, chamomile) runs in single milligrams. No dose has been established by a trial of luteolin itself.
Worth-it leaderboard
Luteolin sits outside the worth-it top 20.
Luteolin sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
No safety signal at supplement doses in the limited human exposure reported; the honest caveat is that total studied human exposure is small. Flavonoids at high doses can affect drug-metabolizing enzymes in vitro; documented clinical interactions for luteolin specifically are absent. Pregnancy data are absent.
Longevity Lab Report
Luteolin news. Graded when it happens.
The grade on this page stays free. The email carries the news on luteolin: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the combination-product literature and the preclinical file, with the absence of any isolating randomized trial stated as the record's central fact. Luteolin entered the queue on list frequency and a protocol mention, not on human data.
- 2026-10-23|Not listed under any goal: no graded human benefit exists to map.
The week's longevity and biohacking news.
This grade for Luteolin rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.